Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate. The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results